Literature DB >> 22687143

Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Jeannie-Marie S Leoutsakos1, Dingfen Han, Michelle M Mielke, Sarah N Forrester, JoAnn T Tschanz, Chris D Corcoran, Robert C Green, Maria C Norton, Kathleen A Welsh-Bohmer, Constantine G Lyketsos.   

Abstract

BACKGROUND: Several observational studies have suggested a link between health status and rate of decline among individuals with Alzheimer's disease (AD). We sought to quantify the relationship in a population-based study of incident AD, and to compare global comorbidity ratings to counts of comorbid conditions and medications as predictors of AD progression.
METHODS: This was a case-only cohort study arising from a population-based longitudinal study of memory and aging, in Cache County, Utah. Participants comprised 335 individuals with incident AD followed for up to 11 years. Patient descriptors included sex, age, education, dementia duration at baseline, and APOE genotype. Measures of health status made at each visit included the General Medical Health Rating (GMHR), number of comorbid medical conditions, and number of non-psychiatric medications. Dementia outcomes included the Mini-Mental State Examination (MMSE), Clinical Dementia Rating - sum of boxes (CDR-sb), and the Neuropsychiatric Inventory (NPI).
RESULTS: Health status tended to fluctuate over time within individuals. None of the baseline medical variables (GMHR, comorbidities, and non-psychiatric medications) was associated with differences in rates of decline in longitudinal linear mixed effects models. Over time, low GMHR ratings, but not comorbidities or medications, were associated with poorer outcomes (MMSE: β = -1.07 p = 0.01; CDR-sb: β = 1.79 p < 0.001; NPI: β = 4.57 p = 0.01).
CONCLUSIONS: Given that time-varying GMHR, but not baseline GMHR, was associated with the outcomes, it seems likely that there is a dynamic relationship between medical and cognitive health. GMHR is a more sensitive measure of health than simple counts of comorbidities or medications. Since health status is a potentially modifiable risk factor, further study is warranted.

Entities:  

Mesh:

Year:  2012        PMID: 22687143      PMCID: PMC3573852          DOI: 10.1017/S104161021200049X

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  43 in total

1.  Improving system of care for older adults with mental illness in the United States. Findings and recommendations for the President's New Freedom Commission on Mental Health.

Authors:  Stephen J Bartels
Journal:  Am J Geriatr Psychiatry       Date:  2003 Sep-Oct       Impact factor: 4.105

2.  The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages.

Authors:  G Dooneief; K Marder; M X Tang; Y Stern
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

Review 3.  Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen Project.

Authors:  H Agüero-Torres; L Fratiglioni; B Winblad
Journal:  Int J Geriatr Psychiatry       Date:  1998-11       Impact factor: 3.485

4.  The Modified Mini-Mental State (3MS) examination.

Authors:  E L Teng; H C Chui
Journal:  J Clin Psychiatry       Date:  1987-08       Impact factor: 4.384

5.  A new clinical scale for the staging of dementia.

Authors:  C P Hughes; L Berg; W L Danziger; L A Coben; R L Martin
Journal:  Br J Psychiatry       Date:  1982-06       Impact factor: 9.319

6.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

Review 7.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

8.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

9.  A validation study of the Dementia Questionnaire.

Authors:  C Kawas; J Segal; W F Stewart; M Corrada; L J Thal
Journal:  Arch Neurol       Date:  1994-09

10.  Education and the course of cognitive decline in Alzheimer disease.

Authors:  R S Wilson; Y Li; N T Aggarwal; L L Barnes; J J McCann; D W Gilley; D A Evans
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

View more
  25 in total

1.  Latent classes of course in Alzheimer's disease and predictors: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Sarah N Forrester; Christopher D Corcoran; Maria C Norton; Peter V Rabins; Martin I Steinberg; Joann T Tschanz; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2014-11-03       Impact factor: 3.485

2.  Dementia: The complexities of comorbidity in dementia.

Authors:  Christopher M Callahan; Cathy C Schubert
Journal:  Nat Rev Neurol       Date:  2014-03-18       Impact factor: 42.937

3.  Neuropsychiatric symptoms in severe dementia: Associations with specific cognitive domains the Cache County Dementia Progression Study.

Authors:  William J Rozum; Bryce Cooley; Elizabeth Vernon; Joshua Matyi; JoAnn T Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2019-04-25       Impact factor: 3.485

4.  The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset.

Authors:  Joann T Tschanz; Maria C Norton; Peter P Zandi; Constantine G Lyketsos
Journal:  Int Rev Psychiatry       Date:  2013-12

Review 5.  The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ.

Authors:  Cong Zheng; Xin-Wen Zhou; Jian-Zhi Wang
Journal:  Transl Neurodegener       Date:  2016-04-05       Impact factor: 8.014

6.  Caregiver-Care Recipient Relationship Closeness is Associated With Neuropsychiatric Symptoms in Dementia.

Authors:  Elizabeth K Vernon; Bryce Cooley; William Rozum; Gail B Rattinger; Stephanie Behrens; Joshua Matyi; Elizabeth Fauth; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Am J Geriatr Psychiatry       Date:  2018-12-01       Impact factor: 4.105

7.  Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.

Authors:  Stephanie Behrens; Gail B Rattinger; Sarah Schwartz; Joshua Matyi; Chelsea Sanders; M Scott DeBerard; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2018-03-21       Impact factor: 3.878

8.  Association Between Accelerated Multimorbidity and Age-Related Cognitive Decline in Older Baltimore Longitudinal Study of Aging Participants without Dementia.

Authors:  Elisa Fabbri; Yang An; Marco Zoli; Toshiko Tanaka; Eleanor M Simonsick; Melissa H Kitner-Triolo; Stephanie A Studenski; Susan M Resnick; Luigi Ferrucci
Journal:  J Am Geriatr Soc       Date:  2016-04-30       Impact factor: 5.562

Review 9.  Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy.

Authors:  C H Latta; H M Brothers; D M Wilcock
Journal:  Neuroscience       Date:  2014-10-05       Impact factor: 3.590

10.  Nutritional Status is Associated With Severe Dementia and Mortality: The Cache County Dementia Progression Study.

Authors:  Chelsea L Sanders; Heidi J Wengreen; Sarah Schwartz; Stephanie J Behrens; Chris Corcoran; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Oct-Dec       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.